公开(公告)号：EP0946561B1

公开(公告)日：2002-02-13

申请号：EP97951356.1

申请日：1997-12-12

申请人： AstraZeneca AB

发明人： BONNERT, Roger ,  INGALL, Anthony ,  SPRINGTHORPE, Brian ,  WILLIS, Paul

IPC分类号： C07D487/04 ,  A61K31/505 ,  A61K31/41

CPC分类号： C07D487/04

摘要： The invention relates to triazolo[4,5-d]pyrimidin-3-yl derivatives of formula (I), which are useful in the treatment of platelet aggregation disorders.

公开(公告)号：EP2144881A1

公开(公告)日：2010-01-20

申请号：EP08718978.3

申请日：2008-04-04

申请人： AstraZeneca AB

发明人： HALLAM, Matthew ,  MARTIN, Barrie ,  RAUBO, Piotr ,  ROBERTS, Bryan ,  ST-GALLAY, Stephen ,  WILLIS, Paul

IPC分类号： C07D217/24 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D487/08 ,  A61K31/4353 ,  A61P11/06

CPC分类号： C07D217/24 ,  C07D217/26 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D487/08

摘要： The present invention relates to isoquinolinone derivatives of formula (I): should be wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：EP0840740B1

公开(公告)日：2002-05-02

申请号：EP96923160.4

申请日：1996-07-04

申请人： AstraZeneca AB

发明人： COX, David ,  INGALL, Anthony ,  WILLIS, Paul

IPC分类号： C07H19/16 ,  C07D487/04 ,  C07D403/04

CPC分类号： C07D487/04 ,  C07H19/06

摘要： Compounds of formula (I), wherein B is O or CH2; X is selected from NR?1R2, SR1¿, and C¿1?-C7 alkyl; Y is selected from SR?1NR1R2¿, and C¿1?-C7 alkyl; R?1 and R2¿ are each and independently selected from H, or C¿1?-C7 alkyl optionally substituted upon or within the alkyl chain by one or more of O, S, N or halogen; R?3 and R4¿ are both H, or R?3 and R4¿ together form a bond; A is COOH, C(O)NH(CH¿2?)pCOOH, C(O)N[(CH2)qCOOH]2; C(O)NHCH(COOH)(CH2)rCOOH, or 5-tetrazolyl, wherein p, q and r are each and independently 1, 2, or 3; as well as pharmaceutically acceptable salts and prodrugs thereof, pharmaceutical compositions comprising the novel compounds and use of the compounds in therapy. Also within the scope of the invention are novel intermediates to the novel compounds. The novel compounds are in particular useful in the prevention of platelet aggregation.

公开(公告)号：EP2035386A1

公开(公告)日：2009-03-18

申请号：EP07748255.2

申请日：2007-06-18

申请人： AstraZeneca AB

发明人： MARTIN, Barrie ,  WILLIS, Paul

IPC分类号： C07D217/24 ,  A61K31/472 ,  A61K31/4725 ,  A61P11/06 ,  A61P17/06 ,  A61P19/02 ,  A61P31/18 ,  A61P9/00 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

CPC分类号： C07D217/24 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12

摘要： The invention concerns a compound of formula (I) or pharmaceutically-acceptable salts thereof wherein R1, R2, R3, R4, R5 and m are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.

公开(公告)号：EP1265899A1

公开(公告)日：2002-12-18

申请号：EP01902950.3

申请日：2001-02-07

申请人： AstraZeneca AB

发明人： BONNERT, Roger ,  CAGE, Peter ,  HUNT, Fraser ,  WALTERS, Lain ,  WILLIS, Paul

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P11/00 ,  A61P17/06 ,  A61P29/00

CPC分类号： C07D473/24

摘要： The invention provides certain heterocyclic compounds, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b).

公开(公告)号：EP1104425A1

公开(公告)日：2001-06-06

申请号：EP99943554.8

申请日：1999-08-03

申请人： AstraZeneca AB

发明人： AUSTIN, Rupert ,  BAXTER, Andrew ,  BONNERT, Roger ,  HUNT, Fraser ,  KINCHIN, Elizabeth ,  WILLIS, Paul

IPC分类号： C07D513/04 ,  A61K31/519 ,  A61K31/426 ,  A61P17/06 ,  A61P29/00

CPC分类号： C07D513/04

摘要： The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

公开(公告)号：EP1824838A1

公开(公告)日：2007-08-29

申请号：EP05810057.9

申请日：2005-11-28

申请人： AstraZeneca AB

发明人： EVANS, Richard ,  FORD, Rhonan ,  THOMPSON, Toby ,  WILLIS, Paul

IPC分类号： C07D401/04 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61P11/06 ,  A61P19/02 ,  A61P19/08 ,  A61P9/10 ,  C07D215/14 ,  C07D215/38 ,  C07D401/06 ,  C07D401/14 ,  C07D413/06

CPC分类号： C07D215/38 ,  C07D215/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D413/06

摘要： The invention provides compounds of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, in which A, n, p, q, R1, R2, R3 and R4 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.

摘要翻译： 本发明提供了式（I）化合物或其药学上可接受的盐或体内可水解的酯，其中A，n，p，q，R 1，R 2，R 3和R 4如说明书中所定义; 他们的准备过程; 含有它们的药物组合物 和它们在治疗中的用途。

公开(公告)号：EP0996621B1

公开(公告)日：2003-10-01

申请号：EP98934107.8

申请日：1998-07-15

申请人： AstraZeneca AB

发明人： GUILE, Simon ,  INGALL, Anthony ,  SPRINGTHORPE, Brian ,  WILLIS, Paul

IPC分类号： C07D487/04 ,  A61K31/505 ,  A61K31/41

CPC分类号： C07D487/04

公开(公告)号：EP1104425B1

公开(公告)日：2003-01-29

申请号：EP99943554.8

申请日：1999-08-03

申请人： AstraZeneca AB

发明人： AUSTIN, Rupert ,  BAXTER, Andrew ,  BONNERT, Roger ,  HUNT, Fraser ,  KINCHIN, Elizabeth ,  WILLIS, Paul

IPC分类号： C07D513/04 ,  A61K31/519 ,  A61K31/426 ,  A61P17/06 ,  A61P29/00

CPC分类号： C07D513/04

摘要： The invention provides certain thiazolopyrimidine compounds of general formula (I), processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

摘要翻译： 本发明提供了通式（I）的某些噻唑并嘧啶化合物，其制备中使用的方法和中间体，含有它们的药物组合物以及它们在治疗中的用途。

公开(公告)号：EP2144881B1

公开(公告)日：2012-06-20

申请号：EP08718978.3

申请日：2008-04-04

申请人： AstraZeneca AB

发明人： HALLAM, Matthew ,  MARTIN, Barrie ,  RAUBO, Piotr ,  ROBERTS, Bryan ,  ST-GALLAY, Stephen ,  WILLIS, Paul

IPC分类号： C07D217/24 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D487/08 ,  A61K31/4353 ,  A61P11/06

CPC分类号： C07D217/24 ,  C07D217/26 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D487/08

摘要： The present invention relates to isoquinolinone derivatives of formula (I): should be wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.